About this trial
With the help of the 'Traditional Chinese Medicine Specialty Alliance Platform-Multicenter RCT Clinical Research Database,' this platform can be used to conduct scientific research on various aspects of DKD, such as disease prediction, treatment effectiveness evaluation, and recurrence rate analysis, providing effective means to improve DKD remission rates, delay disease progression, and enhance patients' quality of life. By selecting the Jiade Yishen Xiaozheng Qufang formula and conducting multicenter, prospective, double-blind RCT studies, its clinical value in improving DKD remission rates can be verified. With the support of scientific research, DKD treatment strategies can be optimized, therapeutic efficacy improved, recurrence rates reduced, and disease progression delayed, thereby enhancing patients' quality of life.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Meets the clinical diagnostic criteria for diabetic nephropathy;
Aged 18-75 years, any gender;
eGFR >45 ml/min/1.73m²;
24-hour urine protein <2.0 g/day;
Disqualifiers
Acute kidney injury or renal function impairment caused by other reasons (recent rapid decline in renal function, or kidney damage caused by drugs, infections, etc.);
Other primary or secondary kidney diseases (such as systemic lupus erythematosus, polycystic kidney disease, etc.);
Uncontrolled severe complications (such as severe cardiovascular disease, uncontrolled hypertension, severe infections, etc.);
Critical organ failure (severe diseases of the heart, liver, or lungs);
Trial design
Parallel
Treatments tested in this trial
Jiajian Yishen Xiaozheng Qufeng Granules
DrugInvolving unlisted drugs, vaccines, medical devices, and other products;Unlisted product type: Medicine;Unlisted product name: Jia Jian Yi Shen Xiao Zheng Qu Feng Fang Granules;Unlisted Product Preparation Organization: Jiangyin Tianjiang Pharmaceutical Co., Ltd.;Type of preparation institution for unlisted products: Domestic (within China).
Treatment groups
Trial outcomes
Primary outcomes
UACR/UAER/24-hour urinary protein returns to normal or decreases by 50% compared with before.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Jiazhen Yin
Lead sponsor
Hangzhou Hospital of Traditional Chinese Medicine
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: